Global Cancer Supportive Care Products Market, By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies) - Industry Trends and Forecast to 2029.
Market Analysis and Size
According to the World Cancer Research Fund International (WCRF), there would be more than 24 million cancer cases worldwide by 2035, with non-melanoma skin cancer not included in the estimates. According to the National Cancer Institute (NIH), more than a million and a half new cancer cases were diagnosed in the United States in 2017. Cancer supportive care products are intended to help patients cope with the negative effects of treatment. As a result, rising cancer rates are directly linked to the expansion of this sector
In 2018, the worldwide cancer burden was expected to have increased to 18.1 million new cases and 9.6 million deaths. Lung and breast cancer are the most common cancers with the highest demand for supportive care medications. Data Bridge Market Research analyses that the cancer supportive care products market was valued at USD 20,124.54 million in 2021 and is further estimated to reach USD 24,519.80 million by 2029, and is expected to grow at a CAGR of 2.5% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
Segments Covered
|
Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
Acacia Pharma Group Plc (Poland), Teva Pharmaceuticals Industries Ltd (Israel), Fagron Group (Poland), KYOWA HAKKO BIO CO., LTD. (Japan), APR (Switzerland), and F. Hoffmann-La Roche Ltd (Switzerland)
|
Market Opportunities
|
|
Market Definition
Nonsteroidal erythropoietin stimulating agents, opioid analgesics, anti-infective drugs, anti-inflammatory drugs, monoclonal antibodies, anti-emetics drugs, bisphosphonates, and granulocyte colony stimulating factor are some of the cancer supportive care products that can be classified by drug class.
Cancer Supportive Care Products Market Dynamics
Drivers
- Rise in the incidence of cancer
According to the American Cancer Society, there will be 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States year 2019.
- Increasing of the aging population
In cancer supportive care, geriatric co-management for cancer patients is successful. According to a retrospective cohort study published in August 2020 in JAMA Network Open titled "association of geriatric management and 90-Day postoperative mortality among patients aged 75 years and older with cancer," geriatric co-management was associated with significantly lower 90-day postoperative mortality among older cancer patients.
- Approval and launch of new products
Increasing the amount of money has been spent on cancer research and development. Cancer research funding by NCRI partners, for example, reached over US$ 750 million in 2018/19, according to the National Cancer Research Institute (NCRI).
Opportunities
In addition, the growing purchasing power of urban population in the advancing countries and government reimbursement programs are further estimated to provide potential opportunities for the growth of the cancer supportive care products market in the coming years.
Restraints/Challenges
On the other hand, the stringent regulation and side effects regarding the cancer drugs affect the quality of life of the patient is further projected to impede the growth of the cancer supportive care products market in the in the targeted period. However, the increasing expenditure of research and development attempts, and the administrating difficulties might further challenge the growth of the cancer supportive care products market in the near future.
This cancer supportive care products market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer supportive care products market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Cancer Supportive Care Products Market
The COVID-19 had a negative impact on the cancer supportive care products market. The COVID-19 epidemic has wreaked havoc on cancer care, causing delays in diagnosis and treatment, as well as the suspension of clinical trials. As a result, healthcare institutions are urgently rearranging cancer services to ensure that patients continue to receive critical care while limiting their exposure to the SARS-CoV-2 virus.
Recent Development
- In August 2020, in a late-stage study, Bristol Myers Squibb stated that Idhifa, which has been approved by the FDA for relapsed or refractory AML with an IDH2 mutation, failed to show efficacy in improving survival in the same patient population when given alongside optimum supportive treatment.
- In September 2020, Merck presented more than 30 abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Global Cancer Supportive Care Products Market Scope and Market Size
The cancer supportive care products market is segmented on the basis of drug class, indication and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Nonsteroidal Anti- Inflammatory Drugs
- Anti-Infective
- Anti-Emetics
- Monoclonal Antibodies
- Erythropoietin Stimulating Agents
- Opioid Analgesics
- Bisphosphonates
- Granulocyte Colony Stimulating Factor
On the basis of drug class, the cancer supportive care products market is segmented into nonsteroidal anti- inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, granulocyte colony stimulating factor.
Indication
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Leukemia, Ovary Cancer
- Melanoma Cancer
- Others
On the basis of indication, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukemia, ovary cancer, melanoma cancer, others.
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Compounding Pharmacies
On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies, compounding pharmacies.
Cancer Supportive Care Products Market Regional Analysis/Insights
The cancer supportive care products market is analysed and market size insights and trends are provided by country, drug class, indication and distribution channel as referenced above.
The countries covered in the cancer supportive care products market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cancer supportive care products market due to the rise in the biosimilars owing to the double the average price of biologics. Furthermore, the increase in the research and development of pharmaceuticals drugs will further boost the growth of the cancer supportive care products market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the rise in the biosimilars in the preceding years. Moreover, the increase in the prevalence of cancer coupled with large number of side-effects and the cancer treatment is further anticipated to propel the growth of the cancer supportive care products market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The cancer supportive care products market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer supportive care products market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer supportive care products market. The data is available for historic period 2010-2020.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
The cancer supportive care products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer supportive care products market.
Some of the major players operating in the cancer supportive care products market are:
- Acacia Pharma Group Plc (Poland)
- Teva Pharmaceuticals Industries Ltd (Israel)
- Fagron Group (Poland)
- KYOWA HAKKO BIO CO., LTD. (Japan)
- APR (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
SKU-